Investigation of inhaled Salmeterol/ Fluticasone propionate (SFC) in patient with COPD.

Investigation of inhaled Salmeterol/ Fluticasone propionate (SFC) in patient with COPD. - SFC for COPD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006589

Enrollment

342

Registered

2011-10-24

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Inhaled Salmeterol/ Fluticasone propionate 100 micro gram Inhaled Salmeterol/ Fluticasone propionate 250 micro gram

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic obstructive pulmonary disease Patients can use the inhaled thearapy Patients gave written informed consent

Exclusion criteria

Exclusion criteria: History of hyper- sensitivity to Salmeterol/ Fluticasone propionate Patients with bronchial asthma Patients during acute exacerbation Presence of infectious disease, pneumothorax, and severe heart failure

Design outcomes

Primary

Measure	Time frame
Changes of FEV1	—

Secondary

Measure	Time frame
QOL, Safety	—

Countries

Japan

Contacts

Public ContactHideki Yasui

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

yassy19781119@yahoo.co.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026